Infarmed warned on Tuesday of supply constraints for drugs used to treat ADHD, calling on healthcare providers and distributors to “prudently manage” existing stocks.
“Some medications for the treatment of attention deficit hyperactivity disorder (methylphenidate, atomoxetine, lisdexamfetamine dimesylate) are creating supply constraints due to increased demand,” the National Medicines and Health Products Administration said in an information circular. Infarmed). on the website.
To ensure the availability of these drugs, Infarmed says, “it is critical that physicians, pharmacists and distributors carefully manage available supplies.”
He also encourages patients to buy medications only when needed, so that the small quantities available can be distributed to everyone who needs them.
Infarmed adds that it is monitoring marketing authorization holder supply and has confirmed that there have been “disruptions in the supply of some medicines, particularly in some strengths”, particularly medicines with the active substance atomoxetine in 40 and 60 milligram capsules, and with methylphenidate, namely in 10 mg tablets and extended-release tablets.
In the document, Infarmed warns prescribers that new treatments should use available drugs whenever possible.
For ongoing treatment, available alternatives should be considered.
“Medicines whose supply is limited should be reserved for those patients whose replacement is difficult,” emphasizes Infarmed.
Author: Lusa
Source: CM Jornal
I’m Dave Martin, and I’m an experienced journalist working in the news industry. As a part of my work, I write for 24 News Reporters, covering mostly sports-related topics. With more than 5 years of experience as a journalist, I have written numerous articles on various topics to provide accurate information to readers.